University at Buffalo

UB is part of joint $17 million NIH grant to study temporomandibular disorders

BUFFALO, N.Y. — Five University at Buffalo researchers are participating in a $17 million multi-institution study funded by ...
Bored Panda on MSN

44 times experts who should’ve known better were shockingly and dangerously wrong

When professionals get it wrong, the consequences can range from awkward to genuinely alarming. This collection brings ...

Combination therapy against brain cancer proves effective in preclinical models

Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...
The American Journal of Managed Care

Rilzabrutinib Offers a New, Well-Tolerated Option for Patients With ITP: David Kuter, MD, DPhil

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.